Drug Design Targeting Phosphodiesterase
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (22 April 2024) | Viewed by 127
Special Issue Editor
Interests: C–H function in drug synthesis; C–H function in the discovery of biological compound discovery; natural product total synthesis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Phosphodiesterases (PDEs) are a superfamily of enzymes that specifically hydrolyze the second messenger cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which can in turn be divided into PDE1-PDE11 subfamilies. At present, more than ten PDE inhibitors are available on the market, including heavy bomb PDE5 inhibitors sildenafil and tadalafil, as well as the PDE4 inhibitor Apremilast. On the other hand, PDE has been demonstrated to be the potential target for various diseases such as heart failure and neurodegenerative diseases. More and more inhibitors are being developed to target different PDE subtypes, which will greatly promote the emergence of new targets for second messenger-related diseases. This SI seeks to solicit research on the development of PDE inhibitors, as well as research related to the application of targeted PDE and chemical probes. Our aim is to provide a platform for discussing the latest research on PDE inhibitors and promoting the application of PDE inhibitors.
Dr. Yinuo Wu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- phosphodiesterase inhibitor
- novel target
- computer-aided drug design
- novel treatment
- novel mechanism
